Syndax Pharmaceuticals Inc (SNDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $850.77M
Last updated: Nov 17, 2026 at 4:15 PM ET
Syndax Pharmaceuticals Inc (SNDX) Statistics
Syndax Pharmaceuticals (SNDX) has a market cap of $850.77M and an enterprise value of $959.62M. Revenue grew 159.46% over the last 12 months from the 12 months before. It kept -72.38% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 12.79% above the market cap, as debt exceeds cash.
| Market Cap | $850.77M |
|---|---|
| Enterprise Value | $959.62M |
| Latest price (Nov 17, 2026) | $9.20 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 2.9x. Its year-end P/S ranged from 8.3x to 597.7x from 2016 to 2025.
| P/S Ratio | 2.9x |
|---|---|
| Forward P/S | 2.7x |
Price Statistics
The stock is down 44.65% over 52 weeks and trades 37.96% below its 50-day average.
| Beta (1Y) | 0.78 |
|---|---|
| 52-Week Change | -44.65% |
| 1-Month Change | -29.72% |
| 3-Month Change | -55.71% |
| 6-Month Change | -52.48% |
| 5-Year Change | -29.82% |
| 10-Year Change | +15.58% |
| Total Return (1Y) | -44.65% |
| Total Return (3Y CAGR) | -15.54% |
| Total Return (5Y CAGR) | -12.42% |
| Return vs SPY (1Y) | -57.73% |
| Max Drawdown (1Y) | -63.70% |
| Max Drawdown (3Y) | -64.81% |
| Sharpe Ratio (1Y) | -1.05 |
| Correlation with SPY (1Y) | 0.18 |
| 50-Day Average | $14.83 |
| 200-Day Average | $19.61 |
| 52-Week Range | $9.06 to $25.59 |
| RSI (14 Days) | 25.8 |
| Average Volume (20 Days) | 3.95M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.69x current liabilities.
| Current Ratio | 4.69x |
|---|---|
| Quick Ratio | 4.37x |
| Interest Coverage | -4.77x |
Returns and Efficiency
Return on invested capital is -65.05% over the last 12 months.
| Return on Assets (ROA) | -30.24% |
|---|---|
| Return on Invested Capital (ROIC) | -65.05% |
| Return on Capital Employed (ROCE) | -32.78% |
| ROA (5Y Average) | -31.30% |
| Asset Turnover | 0.47x |
| Inventory Turnover | 0.62x |
| Receivables Turnover | 6.07x |
| Cash Conversion Cycle | 579 days |
Scores
SNDX has an Altman Z-Score of -2.33, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.33 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $289.43M over the last 12 months.
| Revenue | $289.43M |
|---|---|
| Revenue Growth (YoY) | +159.46% |
| Gross Profit | $266.89M |
| Operating Income | -$178.64M |
| Pretax Income | -$209.48M |
| Net Income | -$209.48M |
| EBIT | -$187.41M |
| Reported EPS (TTM) | -$2.36 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $135.94M |
|---|---|
| Total Debt | $244.79M |
| Net Debt | $108.85M |
| Net Debt Per Share | $1.21 |
| Working Capital | $446.47M |
| Shareholder Equity | -$17.18M |
| Total Assets | $692.67M |
| Total Liabilities | $709.85M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$177.36M |
|---|---|
| FCF Per Share | -$2.00 |
| Depreciation and Amortization | $4.17M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -61.72%.
| Gross Margin | 92.21% |
|---|---|
| Operating Margin | -61.72% |
| Pretax Margin | -72.38% |
| Net Margin | -72.38% |
| EBIT Margin | -64.75% |
Growth
| Revenue Growth (5Y CAGR) | +157.68% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -68.75% |
| Tangible Book Per Share Growth (2Y CAGR) | -68.75% |
Dividends and Yields
SNDX does not pay a dividend.
| Buyback Yield | -0.15% |
|---|---|
| Shareholder Yield | -0.15% |
Peer Position
Against 4 similar companies, SNDX has the 4th highest P/S.
P/S RatioPeer median 18.7x
ROICPeer median -32.76%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 2.9x vs 18.7x median |
|---|---|
| ROIC | -65.05% vs -32.76% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +159.46% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 63.15% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +63.15% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SNDX
What is SNDX's market cap?
Syndax Pharmaceuticals has a market cap of $850.77M. Its enterprise value, which adds debt and subtracts cash, is $959.62M.
How many shares of SNDX are outstanding?
Syndax Pharmaceuticals has 89.79M shares outstanding. The count is up 3.66% from a year earlier.
Does SNDX pay a dividend?
No. Syndax Pharmaceuticals does not pay a dividend.
How much debt does SNDX have?
Syndax Pharmaceuticals has $244.79M of total debt and $135.94M of cash and equivalents, a net debt position of $108.85M.
SNDX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors